NEW YORK, Nov. 18, 2025 /PRNewswire/ -- Renalytix plc (LSE: RENX) (OTCQB: RNLXY), a precision-medicine diagnostics company for kidney health and developer of kidneyintelX.dkd, the only FDA-approved ...
A new study unveiled on day 2 of ESC Congress 2021 showed finerenone, a nonsteroidal mineralocorticoid receptor antagonist, offers benefits to patients with mild to moderate CKD and type 2 diabetes.
Key opinion leaders discuss the clinical significance of dosing flexibility for the CANDOR trial regimen, as studied in the EQUULEUS trial. C. Ola Landgren, MD, PhD: The once-weekly and twice-weekly ...
Among patients with diabetic kidney disease (DKD), those with anemia may especially reap cardiovascular benefits from finerenone treatment. Finerenone treatment reduces cardiovascular and kidney risks ...
LONDON and SALT LAKE CITY, June 29, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (LSE: RENX) (NASDAQ:RNLX) announces that the U.S. Food and Drug Administration (FDA) has granted De Novo marketing ...
—Youth-onset T2D carries a higher risk of diabetic kidney disease than both adult-onset T2D of similar duration and T1D. Is there a path to prevention and slowing progression? The leading cause of end ...
Finerenone reduced the incidence of the primary composite endpoint of CV death, nonfatal MI, nonfatal stroke or hospitalization for heart failure by 13%. The prescribing information for Kerendia ® ...
BEAt-DKD (“Biomarker Enterprise to Attack Diabetic Kidney Disease”), a unique public private partnership, has announced the launch of a 5-year project with the aim to improve prevention and management ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results